Tirzepatide
Also known as: Mounjaro, Zepbound, GIP/GLP-1 dual agonist
Weekly GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for weight management and obstructive sleep apnea.
Evidence
Strong
FDA status
FDA-approved
Source
Synthetic dual GIP/GLP-1 receptor agonist
Overview
Weekly GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for weight management and obstructive sleep apnea.
Mechanism of Action
Activates both GIP and GLP-1 receptors for synergistic metabolic effects, enhances insulin secretion while suppressing glucagon, reduces appetite via hypothalamic pathways, improves insulin sensitivity, may affect energy use.
What research has looked at
Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.
- Weight loss (SURMOUNT trials)
- Blood sugar control in type 2 diabetes
- Reduced appetite and food intake
- Improved insulin sensitivity
- Lower HbA1c
- Fewer breathing interruptions in sleep apnea with obesity (Zepbound)
Researched for
Includes FDA-approved uses where marked; other items are research topics, not approved uses.
How Gabriel approaches peptides
Tirzepatide can be requested through Gabriel. A licensed clinician at a telehealth partner reviews your request and decides whether it's appropriate. Gabriel never gives peptide dosing.
Compounded medications aren't FDA-approved. A licensed clinician decides what's right for you.
Research & Evidence
SURPASS and SURMOUNT trials, FDA approved
SURPASS trials support its use in type 2 diabetes (Mounjaro) and SURMOUNT trials its use for chronic weight management (Zepbound). In December 2024 FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity. In the SURMOUNT-5 trial it produced more weight loss than semaglutide.
Safety Information
Potential Side Effects
- •Nausea
- •Diarrhea
- •Vomiting
- •Constipation
- •Abdominal pain
- •Injection site reactions
- •Fatigue
Contraindications
- Medullary thyroid carcinoma history
- MEN 2 syndrome
- Pregnancy
- Breastfeeding
- Severe GI disease
Interactions
- ⚠Delays gastric emptying
- ⚠May affect oral medication absorption
- ⚠Potentiates insulin
Quick Facts
Related Peptides
AOD-9604
Growth hormone fragment that promotes fat loss through lipolysis without affecting IGF-1 or glucose.
Semaglutide
Weekly GLP-1 receptor agonist, FDA-approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management and other uses.
Retatrutide
Investigational weekly medicine that acts on GIP, GLP-1 and glucagon receptors. It is not FDA-approved and is not available by prescription.